Compare Becton Dickinson and Co (BDX) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Rocket Lab USA Inc — how do they compare? Becton Dickinson and Co trades at $180.66 (market cap $49.41B), while Rocket Lab USA Inc trades at $80.21 (market cap $50.01B). The key difference: Becton Dickinson and Co and Rocket Lab USA Inc are close in size by market cap, and Becton Dickinson and Co pays a 2.32% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| BDX | RKLB | |
|---|---|---|
Market Cap | $49.41B | $50.01B |
Sector | Health | Technology |
52-Week High | $185.39 | $150.23 |
52-Week Low | $138.62 | $39.48 |
Enterprise Value | $65.51B | $47.84B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Rocket Lab (RKLB) trades at $81.06, up 1.27% today, with a bullish technical signal from moving averages and a record $2.36 billion backlog supporting growth. Revenue grew 60% year-over-year in Q2 2026, though net losses persist, and the stock is expensive with a P/S ratio of 60.8. Recent news highlights Neutron rocket development delays but strong contract wins.
The outlook is mixed: analyst consensus is bullish with a $118 price target, but profitability remains elusive until 2027. Key risks include execution on Neutron launches, high valuation, and cash burn. Upside depends on successful scaling and margin improvement from government contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
